{"id":52586,"date":"2023-01-05T16:03:04","date_gmt":"2023-01-05T15:03:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/"},"modified":"2023-01-05T16:03:04","modified_gmt":"2023-01-05T15:03:04","slug":"circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/","title":{"rendered":"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility"},"content":{"rendered":"
\n

\nClears the way for use of its post-consumer resins in food packaging<\/i><\/b>\n<\/p>\n

HOUSTON–(BUSINESS WIRE)–Circulus Holdings, PBLLC (Circulus), a producer of post-consumer resin (PCR) from recycled low-density polyethylene, has recently received a Letter of Non-Objection (LNO) from the U.S. Food and Drug Administration (FDA).\n<\/p>\n

<\/a><\/p>\n

\nThe LNO certifies that Circulus\u2019 recycling process in Riverbank, CA is able to produce 100% recycled PCR suitable for direct food-contact packaging applications. Suitable food packaging applications include direct contact for room temperature, refrigerated, and frozen goods.\n<\/p>\n

\nDavid Hudson, Founder and Chief Strategy Officer of Circulus, stated, \u201cFrom its inception, Circulus has been committed to the goal of producing resin for consumer-facing products and packaging. This development provides important and independent validation that we have achieved our goal, allowing us to move forward in this important market for recycled materials.\u201d\n<\/p>\n

\nCirculus CEO Craig Foster stated, \u201cThis is a huge step forward for Circulus, the circular economy, and for the sustainable packaging industry. Our customers want mechanically recycled resin suitable for the broadest use of applications and Circulus now has the ability to meet this demand.\u201d\n<\/p>\n

\nCirculus is a portfolio company of Ara Partners, a private equity firm that specializes in decarbonization investments.\n<\/p>\n

\nAbout Circulus<\/b>\n<\/p>\n

\nCirculus Holdings, PBLLC is focused on the conversion of plastic waste into post-consumer resins (PCR) utilizing world-class mechanical recycling solutions. Circulus contributes to the circular economy by recycling plastics to their highest and best use while eliminating waste. The company is headquartered in Houston, Texas and currently has facilities in development across the U.S. For more information on Circulus, please visit www.circulus.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Circulus Inquiries:
\n
marketing@circulus.com<\/a>
(832) 699-7459\n<\/p>\n

\nFor media inquiries, contact:
\n
Julia Covini
\n
Pierpont Communications
\n
jcovini@piercom.com<\/a>
(866) 485-4980<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Clears the way for use of its post-consumer resins in food packaging HOUSTON–(BUSINESS WIRE)–Circulus Holdings, PBLLC (Circulus), a producer of post-consumer resin (PCR) from recycled low-density polyethylene, has recently received a Letter of Non-Objection (LNO) from the U.S. Food and Drug Administration (FDA). The LNO certifies that Circulus\u2019 recycling process in Riverbank, CA is able … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52586","6":"format-standard","7":"category-industry"},"yoast_head":"\nCirculus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Clears the way for use of its post-consumer resins in food packaging HOUSTON–(BUSINESS WIRE)–Circulus Holdings, PBLLC (Circulus), a producer of post-consumer resin (PCR) from recycled low-density polyethylene, has recently received a Letter of Non-Objection (LNO) from the U.S. Food and Drug Administration (FDA). The LNO certifies that Circulus\u2019 recycling process in Riverbank, CA is able ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-05T15:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230105005350\/en\/1677683\/21\/circulus-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility\",\"datePublished\":\"2023-01-05T15:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/\"},\"wordCount\":295,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230105005350\\\/en\\\/1677683\\\/21\\\/circulus-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/\",\"name\":\"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230105005350\\\/en\\\/1677683\\\/21\\\/circulus-logo.jpg\",\"datePublished\":\"2023-01-05T15:03:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230105005350\\\/en\\\/1677683\\\/21\\\/circulus-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230105005350\\\/en\\\/1677683\\\/21\\\/circulus-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/","og_locale":"en_US","og_type":"article","og_title":"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility - Pharma Trend","og_description":"Clears the way for use of its post-consumer resins in food packaging HOUSTON–(BUSINESS WIRE)–Circulus Holdings, PBLLC (Circulus), a producer of post-consumer resin (PCR) from recycled low-density polyethylene, has recently received a Letter of Non-Objection (LNO) from the U.S. Food and Drug Administration (FDA). The LNO certifies that Circulus\u2019 recycling process in Riverbank, CA is able ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-05T15:03:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230105005350\/en\/1677683\/21\/circulus-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility","datePublished":"2023-01-05T15:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/"},"wordCount":295,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230105005350\/en\/1677683\/21\/circulus-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/","url":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/","name":"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230105005350\/en\/1677683\/21\/circulus-logo.jpg","datePublished":"2023-01-05T15:03:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230105005350\/en\/1677683\/21\/circulus-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230105005350\/en\/1677683\/21\/circulus-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/circulus-receives-fda-letter-of-non-objection-at-its-riverbank-ca-facility\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Circulus Receives FDA Letter of Non-Objection at its Riverbank, CA Facility"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52586"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52586\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}